老年类风湿关节炎患者与年轻患者使用生物制剂的疗效与安全性比较:系统综述与Meta分析
该系统综述与Meta分析纳入24项研究共63,705例类风湿关节炎患者(24%为老年),比较老年与年轻患者使用生物制剂的疗效与安全性。老年患者基线疾病活动度更差、病程更长(14.4±3.6 vs 10.9±3.6年,p<0.001)、激素使用比例更高(73.2% vs 64.7%,p<0.001);6项评估抗TNF药物的研究中5项显示老年患者疗效更差。抗TNF药物治疗的老年患者感染合并OR为1.59(95%CI 1.45-1.76)、不良反应合并OR为1.40(95%CI 1.23-1.61)。
要点
- 老年RA患者生物制剂疗效与安全性均劣于年轻患者,但基线疾病活动度也更差。
- 抗TNF药物治疗的老年RA患者感染合并OR为1.59(95%CI 1.45-1.76)。
- 抗TNF药物治疗的老年RA患者不良反应合并OR为1.40(95%CI 1.23-1.61)。
核心结论
- 老年RA患者使用生物制剂的疗效与安全性均更差,但其基线疾病活动度也更差。
- 结局报告存在显著异质性,且除抗TNF药物外其他生物制剂的研究非常有限。
研究设计与样本
- 系统综述与Meta分析,检索主要索引数据库,由2名研究者完成综述流程。
- 纳入随机对照试验和观察性研究,研究时长至少6个月,对象为成人RA患者。
- 共纳入24项研究(其中16项聚焦抗TNF药物),代表63,705例患者,24%为老年患者。
- 若4项或以上研究使用相同量表和相同时间框架测量结局,则采用随机效应模型合并效应估计。
主要发现
- 老年RA患者基线RA疾病活动度更差,入组时病程更长(14.4±3.6 vs 10.9±3.6年,p<0.001)。
- 老年RA患者激素使用比例更高(73.2% vs 64.7%,p<0.001)。
- 评估抗TNF药物的6项研究中,5项显示老年患者疗效结局更差。
- 抗TNF药物治疗的老年患者较年轻患者感染合并OR为1.59(95%CI 1.45-1.76)。
- 抗TNF药物治疗的老年患者较年轻患者不良反应合并OR为1.40(95%CI 1.23-1.61)。
关键数值与推荐
- 老年RA患者入组时病程14.4±3.6年 vs 年轻患者10.9±3.6年(p<0.001)。
- 老年RA患者激素使用73.2% vs 年轻患者64.7%(p<0.001)。
- 抗TNF药物治疗的老年患者感染合并OR为1.59(95%CI 1.45-1.76)。
- 抗TNF药物治疗的老年患者不良反应合并OR为1.40(95%CI 1.23-1.61)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 结局报告存在显著异质性。
- 除抗TNF药物外其他生物制剂的研究非常有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Biologic anti-rheumatic drugs are used with less frequency among older patients compared to young patients. This population is less represented in studies performed to evaluate the efficacy and safety of this drugs. We aimed to assess the efficacy and safety of biological agents between the older RA patients compared to young. METHODS: A comprehensive, systematic search was conducted in major indexing databases using key terms for RA and each biological agent. The review process was completed by 2 investigators. Both randomized controlled trials and observational studies of at least 6-month duration conducted in adult RA patients were included. Outcomes of interest were clinical efficacy and safety. Effect-estimates were pooled using random-effects modeling if 4 or more studies used the same scale and time-frame for measuring outcomes. RESULTS: 24 studies (16 focusing on anti-TNF agents) representing 63,705 patients (24% were older) were included. Older RA patients had worse baseline RA disease activity, longer disease duration at the time of enrollment in the trial (14.4 ± 3.6 vs. 10.9 ± 3.6 years; p < 0.001) and higher steroid use (73.2 vs. 64.7%, p < 0.001) than younger. 5 out of 6 studies assessing anti-TNF agents showed worse efficacy outcomes in older patients. The pooled OR of infection and ADRs with anti-TNF agents in older compared to young RA patients was OR 1.59 (95% CI: 1.45-1.76) and 1.40 (95% CI: 1.23-1.61) respectively. CONCLUSIONS: Older patients had worse safety and efficacy with biological agents but also had worse baseline disease activity. There was significant heterogeneity in reporting outcomes and very limited studies in biological agents other than anti-TNF drugs.
引用
- Dalal DS, Duran J, Brar T, et al. Efficacy and safety of biological agents in the older rheumatoid arthritis patients compared to Young: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018. PMID: 30185379. doi:10.1016/j.semarthrit.2018.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。